SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Nurse inserts an IV line into a patient with a mask
COVID-19
FDA Limits Use of Invivyd’s COVID-19 Prophylactic as New Variants Dominate
The regulator’s restrictions come as the U.S. is experiencing a surge in cases. Invivyd also announced updated Phase III data for Pemgarda, touting an 84% relative reduction in symptomatic COVID-19.
August 28, 2024
 · 
2 min read
 · 
Tristan Manalac
Signage at Pfizer's world headquarters in New York City
Business
Pfizer Launches Direct-to-Consumer Portal for Migraine, Flu, COVID-19 Products
The company joins Eli Lilly in offering its own digital platform to more directly connect to patients, allowing them easier access to healthcare providers and prescription drugs.
August 28, 2024
 · 
2 min read
 · 
Tristan Manalac
Podcast
A Tough Ending, New Beginnings and China-U.S. Biopharma Relations
Well-financed startup Tome is winding down operations just as two new companies, Borealis Biosciences and GondolaBio, are launching. Meanwhile, in the midst of already tense relations with China, House lawmakers raise the alarm about U.S. companies working with the country’s military on trials.
August 28, 2024
 · 
1 min read
 · 
Heather McKenzie
Pictured: A syringe broken in half with long hallway in background/Nicole Bean for BioSpace
Vaccines
Moderna Lays Foundations for Growth, but Can It Turn Strategy Into Execution?
The vaccine maker is competing with well-established rivals in markets that have a mix of demand issues as well as commercial and structural headwinds, as the biotech looks to establish new growth drivers.
August 28, 2024
 · 
6 min read
 · 
Nick Paul Taylor
Dry eye disease
Drug Development
Oculis Closes Phase III Eye Drop Trial Due to Third-Party Administrative Error
The company announced Tuesday that despite the error preventing the analysis of late-stage results, the FDA confirmed that data from other completed trials are sufficient to support an NDA submission in the first quarter of 2025.
August 27, 2024
 · 
1 min read
 · 
Annalee Armstrong
D2C Direct to Consumer, eCommerce strategy aimed directly at consumer, Virtual Screen Technology
Mergers & acquisitions
Broken Deals: 4 Pharma Assets Returned to Biotech This Year
Not all licensing deals are successful. Here, BioSpace examines a few noteworthy assets that Big Pharma returned in the last 12 months.
August 27, 2024
 · 
5 min read
 · 
Mollie Barnes
View of Boston architecture, featuring contemporary and historic buildings
Job Trends
Massachusetts’ Biopharma Jobs Grew at Slowed Rate in 2023: Report
Massachusetts’ biopharma jobs increased 2.6% in 2023, according to the MassBio Industry Snapshot. Whether the state’s jobs grow in 2024 remains to be seen based on this year’s layoffs and seemingly slowed hiring based on BioSpace data.
August 27, 2024
 · 
5 min read
 · 
Angela Gabriel
External view of Eli Lilly's world headquarters in Indianapolis
Obesity
Lilly Looks to Expand Zepbound Supply by Offering Single-Dose Vials
Through its online pharmacy LillyDirect, Eli Lilly announced Tuesday it will allow patients to purchase single-dose vials of Zepbound—without the autoinjector—at a 50% discount or more versus other incretin obesity treatments.
August 27, 2024
 · 
3 min read
 · 
Tristan Manalac
3D illustration of tow GLP-1 therapy autoinjectors
Drug pricing
Medicare Coverage of Novo’s Semaglutide for CVD Could Cost $145B Annually: Study
The number of patients who will be eligible for Novo Nordisk’s blockbuster GLP-1 under new Medicare Part D plan guidelines will vary depending on how cardiovascular disease is defined, according to researchers.
August 27, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS